SPINOZA STUDY

You know your roots.
Now explore what's next.

Do you have an elevated risk of **Alzheimer's disease**?

Do you know already the result for an **ApoE testing** or a first-degree relative (parent or sibling) has Alzheimer's disease?

Learn more about our SPINOZA clinical study.



The Spinoza study is testing an investigational drug called obicetrapib to see if it can slow the progression of underlying disease process that can lead to Alzheimer's disease, in people who currently do not have any symptoms.

Preclinical Alzheimer's is the initial "silent" stage of the disease, where brain changes that can be measured through blood based biomarkers have started, but are visible only through health tests such as blood samples as there are no signs of memory loss or cognitive symptoms.

Obicetrapib is an experimental drug that is not yet approved by Health Authorities for treatment of preclinical Alzheimer's disease. Under research development it demonstrated through other clinical trials proof of concept that it may be helpful in delaying the progression of Alzheimer's Disease in individuals with preclinical Alzheimer's Disease by affecting cholesterol metabolism in the brain.

What is involved in the SPINOZA study?

Approximately 400 people will take part in this study at multiple locations globally. The study is divided into 4 parts:

Screening (up to 6 weeks)	During this time you will attend two study visits to complete a number of health tests to determine if you qualify for this study
Study treatment (52 weeks)	Eligible participants will be randomly assigned to one of two treatment groups: • Obicetrapib • Placebo - a substance that looks like the investigational drug, but contains no active ingredients Both groups will take the study treatment daily, by mouth, with food. Neither the participant nor the study doctor will know which treatment they are taking. During this time, participants will be required to attend 6 study visits to monitor their health and study treatment effect.
Extended treatment (26 weeks+)	During this optional stage, following the primary 52 week study, all participants will receive obicetrapib and will be required to attend at least 3 study visits to monitor their health and study treatment effect.
Follow-up (4 weeks)	Following treatment on the study, participants will have a follow-up telephone appointment to monitor their health

For more information please contact: Bri Johnson, 859-257-6507

Thank you for learning about the SPINOZA clinical study.

NewAmsterdam Pharma

© 2026 NewAmsterdam Pharma